BiotechTube

IMVAMUNE®

Phase 3Completed
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smallpox

Conditions

Smallpox

Trial Timeline

Feb 1, 2013 → Jun 1, 2014

NCT ID
NCT01144637

About IMVAMUNE®

IMVAMUNE® is a phase 3 stage product being developed by Bavarian Nordic for Smallpox. The current trial status is completed. This product is registered under clinical trial identifier NCT01144637. Target conditions include Smallpox.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT02038881Phase 2Completed
NCT01144637Phase 3Completed
NCT03472014ApprovedCompleted

Competing Products

20 competing products in Smallpox

See all competitors
ProductCompanyStageHype Score
Smallpox vaccine, LISTER strain, from chick embryo cellsSanofiPhase 2
51
MVA (smallpox vaccine)SanofiPhase 1
32
ACAM3000 MVA VaccineSanofiPhase 1
32
MVA Smallpox vaccine + PlaceboSanofiPhase 2
51
ACAM1000 + vaccinia virus (calf lymph) smallpox vaccine: DryvaxSanofiPhase 2
51
IMVAMUNE (MVA-BN)Bavarian NordicPhase 2
49
MVA-BNBavarian NordicPhase 1
30
IMVAMUNE®Bavarian NordicPhase 2
49
LF formulation of IMVAMUNE® + FD formulation of IMVAMUNE®Bavarian NordicPhase 2
49
IMVAMUNE + IMVAMUNEBavarian NordicPhase 2
49
FD MVA-BNBavarian NordicPhase 3
74
IMVAMUNE + IMVAMUNEBavarian NordicPhase 2
49
MVA-BN® (IMVAMUNE) + PlaceboBavarian NordicPhase 2
49
Elstree-BNBavarian NordicPhase 1
30
ACAM2000Emergent BioSolutionsPhase 3
69
VIGIVEmergent BioSolutionsPre-clinical
15
ACAM2000® smallpox vaccineEmergent BioSolutionsPre-clinical
15
BrincidofovirEmergent BioSolutionsPhase 1
25
Vaccination with ACAM2000Emergent BioSolutionsApproved
77
ACAM2000 Smallpox Vaccine + Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®Emergent BioSolutionsPhase 2
44

Other Products from Bavarian Nordic

IMVAMUNE®Approved
82
VAXCHORA (Cholera Vaccine, Live, Oral)Approved
82
PROSTVAC-V + PROSTVAC-F + GM-CSF + PlaceboPhase 3
74
PXVX0200 + placeboPhase 3
74
MVA-BN standard regimen + MVA-BN standard regimen (Administered as PEP)Phase 3
74